Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Azacitidine with HAAG in AML
NCT06394011Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Feb 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, azacitidine in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Started Feb 2024; status: recruiting.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06394011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06394011.